Latest Medical News – Oncology

Choose Medical News By Speciality

Some feed pages can be slow to load

Our latest Oncology medical news is updated hourly providing the latest news on each feed to ensure that you have all the latest information available in one easy to reach resource.

Doctors Lounge RSS

Melanoma Can Strike Your Nails: Here’s How to Check
on May 16, 2021 at 6:00 pm
Time, Costs of Participation in MIPS Are Considerable
on May 15, 2021 at 2:14 am
Mean cost to practices per physician $12,811; 201.7 hours annually spent per physician on MIPS-related activities
Depression Even More Common With Heart Failure Than Cancer
on May 14, 2021 at 5:11 pm
Noninvasive Markers Aid Risk Assessment of Prostate Cancer
on May 13, 2021 at 8:31 pm
Model combining measurement of EN2 protein marker and levels of 10 genes in urine could reduce unnecessary biopsies
American Medical Association Vows to Confront Racism Among Doctors
on May 13, 2021 at 2:32 am
With about 270,000 members, the AMA represents a little more than 25 percent of U.S. doctors

Oncology – ClinOwl The wider, wiser view

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
by ClinOwl on May 14, 2021 at 11:00 pm
Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody-drug [...]
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
by ClinOwl on May 13, 2021 at 11:00 pm
Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. [...]
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
by ClinOwl on May 13, 2021 at 11:00 pm
The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a [...]
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
by ClinOwl on May 13, 2021 at 11:00 pm
Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Given [...]
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
by ClinOwl on May 13, 2021 at 11:00 pm
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis. Loncastuximab tesirine is [...]

NEJM Journal Watch: Oncology And Hematology RSS Feed Summaries of and commentary on oncology and hematology medical journal articles covering topics such as breast cancer, gastrointestinal cancer, genitourinary cancer, lung cancer, head and neck cancers, malignant hematology, and benign hematology.

ARTIST 2: Implications for Treatment of Node-Positive Gastric Cancer
by David H. Ilson, MD, PhD on May 18, 2021 at 2:18 am
A new trial compares two adjuvant chemotherapy regimens and the addition of radiotherapy.
A New Therapeutic Option for Advanced Urothelial Cancer
by Robert Dreicer, MD, MS, MACP, FASCO on May 18, 2021 at 2:18 am
Sacituzumab govitecan, an antibody–drug conjugate, yielded a 27% objective response rate in patients with progressive disease following platinum-based chemotherapy and immunotherapy.
Mutational Profiling and Cancer-Associated Thrombosis
by Brady L. Stein, MD, MHS on May 18, 2021 at 2:18 am
Six mutations are associated with an increased risk for cancer-associated thrombosis, independent of cancer type.
Total Neoadjuvant Therapy in Rectal Cancer Increases Pathologic Complete Response
by David H. Ilson, MD, PhD on May 18, 2021 at 2:18 am
Disease-free survival at 3 years was also increased with total neoadjuvant therapy compared with standard of care therapy.
A Second-Line Therapy for Cholangiocarcinoma Is Modestly Effective
by David H. Ilson, MD, PhD on May 18, 2021 at 2:18 am
FOLFOX was associated with a limited response and modestly prolonged survival.

Latest Medical News – Oncology

Hysteroscopy Instruments Brochure

Single Use Bipolar Forceps Brochure

Single Use Tubing Sets Brochure